Though all of the studies focused on the same primary endpoint, hospitalizations due to heart failure, the results differed across studies
, , , , , , , , ,
We then move to repair by targeting mitochondrial dysfunction, chronic neuroinflammation, glymphatic stasis, and synaptic loss through multimodal bio-interventionsspecifically advanced Photobiomodulation, ketogenic metabolic switching, electromagnetic field therapies, and targeted peptide supplementation
CLINICAL PRE-APPROVAL REQUIRED This is an advanced, medical-grade formulation
These advanced formulations could potentially overcome the pharmacokinetic limitations that have historically constrained SFNs clinical efficacy
At a molecular level, nothing fundamental has changed